Damien M. Cronier

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

Amita Patnaik, Lee S. Rosen, Sara M. Tolaney et al. · Cancer Discovery · 2016 · 760 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

William D. Tap, Robin L. Jones, Brian A. Van Tine et al. · The Lancet · 2016 · 588 citations

Medicine, Oncology, Pharmacology +9

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Lawrence M. Gelbert, Shufen Cai, Xi Lin et al. · Investigational New Drugs · 2014 · 565 citations · Full text

Medicine, Oncology, Pharmacology +17

Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts

Sonya C. Tate, Shufen Cai, Rose T. Ajamie et al. · Clinical Cancer Research · 2014 · 127 citations · Full text

Medicine, Oncology, Pharmacology +16

A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models

Tinggui Yin, Marı́a José Lallena, Emiko L. Kreklau et al. · Molecular Cancer Therapeutics · 2014 · 101 citations · Full text

Medicine, Cancer Biology, Oncology +13